TNGX

Tango Therapeutics Inc. a biotechnology company discovers and develops drugs for the treatment of cancer. Its lead program is TNG908 a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462 an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260 a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348 an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics Inc. has a strategic collaboration with Gilead Sciences Inc. for the discovery development and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston Massachusetts.